Trump Says Anthropic No Longer Seen as National Security Threat 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
BHP Shares Fall as Jansen Potash Project Costs Surge 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
NEWARK, Calif., Jan. 27, 2016 -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will hold an Analyst and Investor Day in New York City on Wednesday, March 23, 2016 from 9:00 a.m. ET – 11:30 a.m. ET (6:00 a.m. PT – 8:30 a.m. PT). Depomed’s President and Chief Executive Officer Jim Schoeneck and members of the company's management team will be joined by Joseph V. Pergolizzi, Jr., MD, an Adjunct Assistant Professor in the Department of Medicine at Johns Hopkins University School of Medicine in Baltimore, Maryland and an internationally recognized leader in the area of pain medicine and management. The event will provide a business overview as well as a review of the marketed and development-stage product pipeline.
Space is limited and attendance is by invitation only. The presentations, as well as the question and answer session, will be webcast and will be accessible via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcast will be archived for 30 days. Additional event details will be available closer to the event date.
About Depomed
Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payors we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit www.depomed.com
Investor Contact: Christopher Keenan VP, Investor Relations and Corporate Communications 510-744-8000 [email protected]
